Actively Recruiting

All Genders
NCT06456697

Pipeline Embolization Device for the Treatment of Intracranial Aneurysms on the Long Term Safety and Efficacy

Led by Xuanwu Hospital, Beijing · Updated on 2024-06-13

482

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

Sponsors

X

Xuanwu Hospital, Beijing

Lead Sponsor

H

Henan Provincial People's Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Since its launch in China in 2014, Pipeline Embolization Device (PED) has been widely used in the treatment of intracranial aneurysms. It is necessary to collect data on the long-term safety and efficacy of the Pipeline Embolization Device (PED) in the treatment of intracranial aneurysms, analyze its long-term effectiveness, and provide guidance for clinical practice.

CONDITIONS

Official Title

Pipeline Embolization Device for the Treatment of Intracranial Aneurysms on the Long Term Safety and Efficacy

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with intracranial aneurysms using digital subtraction angiography (DSA)
  • Pipeline device successfully placed to treat intracranial aneurysms
Not Eligible

You will not qualify if you...

  • Previous surgery or interventional treatment before enrollment
  • Use of other types of stents during treatment
  • Unable to complete follow-up

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Xuanwu Hospital, Capital Medical University

Beijing, China

Actively Recruiting

Loading map...

Research Team

P

peng zhang, MD

CONTACT

Y

Yongjie Ma, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here